

INDGN/SE/2026-27/62

26 October 2026

|                                                                                                             |                                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BSE Limited,<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street,<br>Mumbai- 400001, India.<br>Scrip Code: 544172 | National Stock Exchange of India Limited<br>Exchange Plaza, C-1, Block G,<br>Bandra Kurla Complex, Bandra (E),<br>Mumbai - 400 051, India.<br>Trading symbol: INDGN |
|-------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Dear Sir / Madam,

**Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the applicable SEBI Circulars, we wish to inform you that a step-down wholly owned subsidiary of Indegene Limited ("Company"), INDEGENE PORTUGAL, UNIPESSOAL LDA, was incorporated on 23 October 2026.

Indegene Ireland Limited, a wholly owned subsidiary of the Company, holds 100% of the share capital of INDEGENE PORTUGAL, UNIPESSOAL LDA.

The Company received the communication confirming the incorporation of the said entity on 26 October 2026.

The disclosure as required under Regulation 30 of SEBI LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is mentioned in "Annexure-I".

This will also be posted on the company's website at: <https://www.indegene.com/>

We request you to kindly take the same on record.

Thanking You

Yours Sincerely,

**For Indegene Limited**

**SRISHTI**  
**RAMESH**  
**KAUSHIK**

Digitally signed by  
SRISHTI RAMESH  
KAUSHIK  
Date: 2026.10.26  
16:13:05 +05'30'

**Srishti Ramesh Kaushik**

**Company Secretary and Compliance Officer**

Encl: A/a



Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy  
Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-  
560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777  
compliance.officer@indegene.com  
www.indegene.com

CIN: L73100KA1998PLC102040

| Sr. No | Particulars                                                                                                                                                                                                                                                                    | Description                                                                                                                                                                                                                                                                                                                  |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1      | Name of the target entity, details in brief such as size, turnover etc.;                                                                                                                                                                                                       | Indegene Portugal, Unipessoal LDA ("Subsidiary")<br><br>Indegene Ireland Limited, a wholly owned subsidiary of the Company, holds 100% of the share capital of INDEGENE PORTUGAL, UNIPESSOAL LDA.<br><br>Turnover – Nil; the entity is yet to begin operations                                                               |
| 2      | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length" | The Subsidiary was incorporated in Portugal by Indegene Ireland Limited. As the entity is yet to begin operations, there are no related party transactions as on date.                                                                                                                                                       |
| 3      | Industry to which the entity being acquired belongs                                                                                                                                                                                                                            | Services for the life sciences, healthcare, and biopharmaceutical sectors;<br>Corporate services for other affiliated entities; Content development and technology support services; Support services related to clinical development and medical affairs; Support services related to medical education and communications. |
| 4      | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)                                                                           | To establish presence in Portugal.                                                                                                                                                                                                                                                                                           |
| 5      | Brief details of any governmental or regulatory approvals required for the acquisition                                                                                                                                                                                         | Not applicable                                                                                                                                                                                                                                                                                                               |
| 6      | Indicative time period for completion of the acquisition                                                                                                                                                                                                                       | Incorporated on 23 October 2026                                                                                                                                                                                                                                                                                              |
| 7      | Consideration – whether cash consideration or share swap or any other form and details of the same                                                                                                                                                                             | Not applicable                                                                                                                                                                                                                                                                                                               |
| 8      | Cost of acquisition or the price at which the shares are acquired                                                                                                                                                                                                              | Not applicable                                                                                                                                                                                                                                                                                                               |
| 9      | Percentage of shareholding/ control acquired and/or number of shares acquired                                                                                                                                                                                                  | 100% of the shareholding is held by Indegene Ireland Limited, a wholly owned subsidiary of Indegene Limited                                                                                                                                                                                                                  |
| 10     | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)                         | The Subsidiary was incorporated in Portugal on 23 October 2026                                                                                                                                                                                                                                                               |